Clinical characteristics and outcomes of patients with coronary artery disease and Angina: Analysis of the irbesartan in patients with heart failure and preserved systolic function trial

Circulation: Heart Failure

Volumn 8, Issue 4, 2015, Pages 717-724

  Badar, Athar A ^a,b   Perez Moreno, Ana Cristina ^a   Hawkins, Nathaniel M ^c   Jhund, Pardeep S ^a   Brunton, Alan P T ^a   Anand, Inder S ^d   McKelvie, Robert S ^e   Komajda, Michel ^f   Zile, Michael R ^g   Carson, Peter E ^h   Gardner, Roy S ^a,b   Petrie, Mark C ^a,b   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VA MEDICAL CENTER   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

Author keywords

Angina Pectoris; Coronary Artery Disease; Heart Failure; Human; Irbesartan

Indexed keywords

IRBESARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS; COMPARATIVE STUDY; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTOLE; TIME; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; SYSTOLE; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84942870082     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.002024     Document Type: Article

References (18)

1. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(25 pt A):2817-2827. doi: 10.1016/j.jacc.2014.03.034.
2. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: Analysis of the CASS registry. J Am Coll Cardiol. 1991;18:377-382.
3. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119:3070-3077. doi: 10.1161/CIRCULATIONAHA.108.815944.
4. Rusinaru D, Houpe D, Szymanski C, Lévy F, Maréchaux S, Tribouilloy C. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail. 2014;16:967-976. doi: 10.1002/ejhf.142.
5. Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail. 2012;18:749-754. doi: 10.1016/j.cardfail.2012.08.357.
6. Al-Khatib SM, Shaw LK, OConnor C, Kong M, Califf RM. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231-1235. doi: 10.1111/j.1540-8167.2007.00957.x.
7. Camici PG, dAmati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol. 2015;12:48-62 doi: 10.1038/nrcardio.2014.160.
8. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467. doi: 10.1056/NEJMoa0805450.
9. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G; I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005;11:576-585. doi: 10.1016/j. cardfail.2005.06.432.
10. McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10:149-156. doi: 10.1016/j. ejheart.2007.12.010.
11. Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, McKelvie RS, Massie B, Carson PE. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2014;16:1175-1182. doi: 10.1002/ejhf.172.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
13. Gray B. Subdistribution analysis of competing risks. The cmprsk library (v 2.2-6). 2013. http://cran.r-project.org. Accessed April 22, 2015.
14. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4:27-35. doi: 10.1161/CIRCHEARTFAILURE.109.932996.
15. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j.jacc.2013.02.092.
16. Badar AA, Perez-Moreno AC, Hawkins NM, Brunton AP, Jhund PS, Wong CM, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Gardner RS, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. Eur J Heart Fail. 2015;17:196-204. doi: 10.1002/ejhf.221.
17. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421-428.
18. Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, Turner RM, Poole-Wilson PA, Davies SW, Sutton GC. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22:228-236. doi: 10.1053/euhj.2000.2289.